Lantern Pharma (NASDAQ:LTRN) Director Lee Troy Schalop Purchases 48,544 Shares

Lantern Pharma Inc. (NASDAQ:LTRN) Director Lee Troy Schalop purchased 48,544 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were purchased at an average price of $2.06 per share, with a total value of $100,000.64. Following the completion of the purchase, the director directly owned 48,544 shares of the company’s stock, valued at $100,000.64. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Lantern Pharma Price Performance

Shares of NASDAQ:LTRN opened at $3.13 on Friday. The firm has a market capitalization of $35.40 million, a PE ratio of -1.99 and a beta of 2.10. The business has a 50-day moving average of $2.22 and a two-hundred day moving average of $2.92. Lantern Pharma Inc. has a 12 month low of $1.11 and a 12 month high of $5.74.

Lantern Pharma (NASDAQ:LTRN) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.10.

Hedge Funds Weigh In On Lantern Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of LTRN. Cetera Investment Advisers purchased a new position in Lantern Pharma in the 4th quarter worth approximately $37,000. XTX Topco Ltd purchased a new position in Lantern Pharma in the 2nd quarter worth approximately $40,000. CIBC Private Wealth Group LLC purchased a new position in Lantern Pharma in the fourth quarter valued at about $47,000. Two Sigma Investments LP acquired a new stake in Lantern Pharma during the 3rd quarter valued at approximately $70,000. Finally, Renaissance Technologies LLC grew its stake in Lantern Pharma by 5.1% during the 1st quarter. Renaissance Technologies LLC now owns 116,000 shares of the company’s stock valued at $159,000 after purchasing an additional 5,600 shares in the last quarter. Hedge funds and other institutional investors own 28.62% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on LTRN. Wall Street Zen raised Lantern Pharma to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

About Lantern Pharma

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.